vs

Side-by-side financial comparison of Phoenix Education Partners, Inc. (PXED) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Phoenix Education Partners, Inc. is the larger business by last-quarter revenue ($222.5M vs $151.7M, roughly 1.5× Tarsus Pharmaceuticals, Inc.). Phoenix Education Partners, Inc. runs the higher net margin — 4.8% vs -5.5%, a 10.4% gap on every dollar of revenue. Phoenix Education Partners, Inc. produced more free cash flow last quarter ($43.5M vs $13.0M).

The University of Phoenix (UoPX) is a private for-profit university headquartered in Phoenix, Arizona. Founded in 1976, the university confers certificates and degrees at the certificate, associate, bachelor's, master's, and doctoral degree levels. It is institutionally accredited by the Higher Learning Commission and has an open enrollment admissions policy for many undergraduate programs. The school is owned by Phoenix Education Partners.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

PXED vs TARS — Head-to-Head

Bigger by revenue
PXED
PXED
1.5× larger
PXED
$222.5M
$151.7M
TARS
Higher net margin
PXED
PXED
10.4% more per $
PXED
4.8%
-5.5%
TARS
More free cash flow
PXED
PXED
$30.5M more FCF
PXED
$43.5M
$13.0M
TARS

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
PXED
PXED
TARS
TARS
Revenue
$222.5M
$151.7M
Net Profit
$10.8M
$-8.4M
Gross Margin
Operating Margin
6.3%
-5.3%
Net Margin
4.8%
-5.5%
Revenue YoY
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$0.28
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PXED
PXED
TARS
TARS
Q1 26
$222.5M
Q4 25
$262.0M
$151.7M
Q3 25
$118.7M
Q2 25
$102.7M
Q1 25
$78.3M
Q4 24
$66.4M
Q3 24
$48.1M
Q2 24
$40.8M
Net Profit
PXED
PXED
TARS
TARS
Q1 26
$10.8M
Q4 25
$15.5M
$-8.4M
Q3 25
$-12.6M
Q2 25
$-20.3M
Q1 25
$-25.1M
Q4 24
$-23.1M
Q3 24
$-23.4M
Q2 24
$-33.3M
Operating Margin
PXED
PXED
TARS
TARS
Q1 26
6.3%
Q4 25
9.8%
-5.3%
Q3 25
-12.2%
Q2 25
-21.6%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Net Margin
PXED
PXED
TARS
TARS
Q1 26
4.8%
Q4 25
5.9%
-5.5%
Q3 25
-10.6%
Q2 25
-19.8%
Q1 25
-32.1%
Q4 24
-34.8%
Q3 24
-48.7%
Q2 24
-81.6%
EPS (diluted)
PXED
PXED
TARS
TARS
Q1 26
$0.28
Q4 25
$0.40
$-0.17
Q3 25
$-0.30
Q2 25
$-0.48
Q1 25
$-0.64
Q4 24
$-0.57
Q3 24
$-0.61
Q2 24
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PXED
PXED
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$201.4M
$417.3M
Total DebtLower is stronger
$58.8M
$72.4M
Stockholders' EquityBook value
$291.1M
$343.4M
Total Assets
$546.4M
$562.2M
Debt / EquityLower = less leverage
0.20×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PXED
PXED
TARS
TARS
Q1 26
$201.4M
Q4 25
$163.5M
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Total Debt
PXED
PXED
TARS
TARS
Q1 26
$58.8M
Q4 25
$61.6M
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
PXED
PXED
TARS
TARS
Q1 26
$291.1M
Q4 25
$280.4M
$343.4M
Q3 25
$335.1M
Q2 25
$332.6M
Q1 25
$342.5M
Q4 24
$224.5M
Q3 24
$237.5M
Q2 24
$252.2M
Total Assets
PXED
PXED
TARS
TARS
Q1 26
$546.4M
Q4 25
$549.6M
$562.2M
Q3 25
$534.6M
Q2 25
$495.0M
Q1 25
$500.8M
Q4 24
$377.0M
Q3 24
$376.3M
Q2 24
$376.8M
Debt / Equity
PXED
PXED
TARS
TARS
Q1 26
0.20×
Q4 25
0.22×
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PXED
PXED
TARS
TARS
Operating Cash FlowLast quarter
$48.9M
$19.3M
Free Cash FlowOCF − Capex
$43.5M
$13.0M
FCF MarginFCF / Revenue
19.6%
8.6%
Capex IntensityCapex / Revenue
2.4%
4.2%
Cash ConversionOCF / Net Profit
4.53×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PXED
PXED
TARS
TARS
Q1 26
$48.9M
Q4 25
$31.1M
$19.3M
Q3 25
$18.3M
Q2 25
$-29.4M
Q1 25
$-20.7M
Q4 24
$-22.2M
Q3 24
$-8.7M
Q2 24
$-14.4M
Free Cash Flow
PXED
PXED
TARS
TARS
Q1 26
$43.5M
Q4 25
$26.4M
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
FCF Margin
PXED
PXED
TARS
TARS
Q1 26
19.6%
Q4 25
10.1%
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Capex Intensity
PXED
PXED
TARS
TARS
Q1 26
2.4%
Q4 25
1.8%
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Cash Conversion
PXED
PXED
TARS
TARS
Q1 26
4.53×
Q4 25
2.01×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons